Watch for Andexxa, a New Anticoagulant Reversal Agent

Andexxa (an-DEK-sah, inactivated recombinant factor Xa) will be a new, IV direct oral anticoagulant (DOAC) reversal agent.

Until now, the only reversal agent for the DOACs was Praxbind (idarucizumab). But it only inactivates Pradaxa (dabigatran)...a direct thrombin inhibitor.

Andexxa will be bigger's an antidote for two factor Xa inhibitors, Eliquis (apixaban) or Xarelto (rivaroxaban).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote